VIB VERMOEGEN AG (VIH1.DE) Fundamental Analysis & Valuation

FRA:VIH1 • DE000A2YPDD0

8.5 EUR
-0.02 (-0.23%)
Last: Mar 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This VIH1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to VIH1. VIH1 was compared to 74 industry peers in the Real Estate Management & Development industry. VIH1 has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on VIH1.


Dividend Valuation Growth Profitability Health

6

1. VIH1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year VIH1 was profitable.
  • VIH1 had a positive operating cash flow in the past year.
  • VIH1 had positive earnings in each of the past 5 years.
  • VIH1 had a positive operating cash flow in each of the past 5 years.
VIH1.DE Yearly Net Income VS EBIT VS OCF VS FCFVIH1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

  • With a Return On Assets value of 1.69%, VIH1 perfoms like the industry average, outperforming 58.11% of the companies in the same industry.
  • With a Return On Equity value of 3.99%, VIH1 perfoms like the industry average, outperforming 59.46% of the companies in the same industry.
  • VIH1's Return On Invested Capital of 3.21% is fine compared to the rest of the industry. VIH1 outperforms 67.57% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for VIH1 is in line with the industry average of 3.95%.
Industry RankSector Rank
ROA 1.69%
ROE 3.99%
ROIC 3.21%
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
VIH1.DE Yearly ROA, ROE, ROICVIH1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 34.63%, VIH1 is in the better half of the industry, outperforming 75.68% of the companies in the same industry.
  • VIH1's Profit Margin has declined in the last couple of years.
  • VIH1 has a better Operating Margin (70.15%) than 90.54% of its industry peers.
  • In the last couple of years the Operating Margin of VIH1 has declined.
  • VIH1's Gross Margin of 78.88% is fine compared to the rest of the industry. VIH1 outperforms 68.92% of its industry peers.
  • VIH1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 70.15%
PM (TTM) 34.63%
GM 78.88%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
VIH1.DE Yearly Profit, Operating, Gross MarginsVIH1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. VIH1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VIH1 is destroying value.
  • Compared to 1 year ago, VIH1 has about the same amount of shares outstanding.
  • VIH1 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, VIH1 has an improved debt to assets ratio.
VIH1.DE Yearly Shares OutstandingVIH1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
VIH1.DE Yearly Total Debt VS Total AssetsVIH1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 0.68, we must say that VIH1 is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.68, VIH1 is in line with its industry, outperforming 41.89% of the companies in the same industry.
  • VIH1 has a debt to FCF ratio of 10.39. This is a negative value and a sign of low solvency as VIH1 would need 10.39 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 10.39, VIH1 is doing good in the industry, outperforming 72.97% of the companies in the same industry.
  • VIH1 has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
  • VIH1 has a Debt to Equity ratio (1.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 10.39
Altman-Z 0.68
ROIC/WACC0.75
WACC4.29%
VIH1.DE Yearly LT Debt VS Equity VS FCFVIH1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • VIH1 has a Current Ratio of 1.03. This is a normal value and indicates that VIH1 is financially healthy and should not expect problems in meeting its short term obligations.
  • VIH1 has a Current ratio (1.03) which is in line with its industry peers.
  • A Quick Ratio of 1.03 indicates that VIH1 should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.03, VIH1 is in the better half of the industry, outperforming 62.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
VIH1.DE Yearly Current Assets VS Current LiabilitesVIH1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. VIH1.DE Growth Analysis

3.1 Past

  • The earnings per share for VIH1 have decreased strongly by -72.11% in the last year.
  • VIH1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.74% yearly.
  • The Revenue has been growing slightly by 4.50% in the past year.
  • VIH1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.78% yearly.
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%

3.2 Future

  • VIH1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.54% yearly.
  • Based on estimates for the next years, VIH1 will show a quite strong growth in Revenue. The Revenue will grow by 10.81% on average per year.
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIH1.DE Yearly Revenue VS EstimatesVIH1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VIH1.DE Yearly EPS VS EstimatesVIH1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

9

4. VIH1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 7.80, the valuation of VIH1 can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of VIH1 indicates a rather cheap valuation: VIH1 is cheaper than 82.43% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.25, VIH1 is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 3.89, the valuation of VIH1 can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, VIH1 is valued cheaper than 97.30% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.39. VIH1 is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 7.8
Fwd PE 3.89
VIH1.DE Price Earnings VS Forward Price EarningsVIH1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • VIH1's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VIH1 is cheaper than 93.24% of the companies in the same industry.
  • VIH1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VIH1 is cheaper than 90.54% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.83
EV/EBITDA 6.08
VIH1.DE Per share dataVIH1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of VIH1 may justify a higher PE ratio.
PEG (NY)0.75
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

1

5. VIH1.DE Dividend Analysis

5.1 Amount

  • VIH1 has a yearly dividend return of 0.41%, which is pretty low.
  • VIH1's Dividend Yield is comparable with the industry average which is at 4.13.
  • Compared to an average S&P500 Dividend Yield of 1.82, VIH1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.41%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
VIH1.DE Yearly Dividends per shareVIH1.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2024 2025 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2Y11.54%
EPS Next 3YN/A
VIH1.DE Yearly Income VS Free CF VS DividendVIH1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

More info and screens

Find the best dividend stocksShow peers with best dividend

VIH1.DE Fundamentals: All Metrics, Ratios and Statistics

VIB VERMOEGEN AG

FRA:VIH1 (3/10/2026, 7:00:00 PM)

8.5

-0.02 (-0.23%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)N/A
Earnings (Next)04-29
Inst Owners0.84%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap280.92M
Revenue(TTM)104.37M
Net Income(TTM)36.14M
Analysts82.86
Price Target11.73 (38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.41%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 7.8
Fwd PE 3.89
P/S 2.69
P/FCF 2.83
P/OCF 2.83
P/B 0.31
P/tB 0.32
EV/EBITDA 6.08
EPS(TTM)1.09
EY12.82%
EPS(NY)2.18
Fwd EY25.68%
FCF(TTM)3.01
FCFY35.36%
OCF(TTM)3.01
OCFY35.36%
SpS3.16
BVpS27.39
TBVpS26.47
PEG (NY)0.75
PEG (5Y)N/A
Graham Number25.92
Profitability
Industry RankSector Rank
ROA 1.69%
ROE 3.99%
ROCE 3.73%
ROIC 3.21%
ROICexc 3.25%
ROICexgc 3.3%
OM 70.15%
PM (TTM) 34.63%
GM 78.88%
FCFM 95.17%
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
ROICexc(3y)4.4%
ROICexc(5y)4.63%
ROICexgc(3y)4.52%
ROICexgc(5y)4.7%
ROCE(3y)4.69%
ROCE(5y)5.03%
ROICexgc growth 3Y-10.75%
ROICexgc growth 5Y-3.98%
ROICexc growth 3Y-11.34%
ROICexc growth 5Y-4.36%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 10.39
Debt/EBITDA 4.3
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 46.63%
Profit Quality 274.83%
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z 0.68
F-Score4
WACC4.29%
ROIC/WACC0.75
Cap/Depr(3y)0.86%
Cap/Depr(5y)88.75%
Cap/Sales(3y)0.31%
Cap/Sales(5y)0.52%
Profit Quality(3y)144.88%
Profit Quality(5y)156.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.54%
EBIT growth 3Y-3.27%
EBIT growth 5Y0.72%
EBIT Next Year69.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.92%
FCF growth 3Y6.73%
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3Y6.76%
OCF growth 5Y5.7%

VIB VERMOEGEN AG / VIH1.DE FAQ

What is the fundamental rating for VIH1 stock?

ChartMill assigns a fundamental rating of 5 / 10 to VIH1.DE.


Can you provide the valuation status for VIB VERMOEGEN AG?

ChartMill assigns a valuation rating of 9 / 10 to VIB VERMOEGEN AG (VIH1.DE). This can be considered as Undervalued.


What is the profitability of VIH1 stock?

VIB VERMOEGEN AG (VIH1.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for VIH1 stock?

The financial health rating of VIB VERMOEGEN AG (VIH1.DE) is 4 / 10.